EU First For Pegfilgrastim Biosimilars? EMA Decides This Week

 
• By Neena Brizmohun

Two biosimilar versions of Amgen’s blockbuster drug, Neulasta, are up for an opinion from the European Medicines Agency this week on whether they should be approved in the EU. Coherus is the sponsor of one of the products.

Concept of national healthcare system - EU - European Union
Biosimilar versions of Neulasta could be available in the EU soon • Source: Shutterstock

More from Product Reviews

More from Pink Sheet